Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats

I. Date, T. Shingo, H. Yoshida, K. Fujiwara, K. Kobayashi, A. Takeuchi, T. Ohmoto

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

In order to deliver glial cell line-derived neurotrophic factor (GDNF) into the brain, we have established a cell line that produces GDNF in a continuous fashion by genetic engineering. These cells were encapsulated and grafted into parkinsonian model rats that had received unilateral intrastriatal injection of 6-hydroxydopamine 2 weeks earlier. Neurochemical analysis showed that GDNF has been produced from the capsule for 6 months after grafting and histological analysis revealed good survival of GDNF-producing cells in the capsule 6 months after grafting. The density of nigrostriatal dopaminergic fibers in the striatum as well as the number of dopaminergic cell bodies in the substantia nigra recovered significantly after GDNF-producing cell grafting. These results suggest the possible application of GDNF-producing cell grafting for the treatment of Parkinson's disease.

Original languageEnglish
Pages (from-to)397-401
Number of pages5
JournalCell Transplantation
Volume10
Issue number4-5
DOIs
Publication statusPublished - 2001

Keywords

  • Encapsulation
  • Glial cell line-derived neurotrophic factor GDNF)
  • Neural transplantation
  • Parkinson's disease

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Fingerprint Dive into the research topics of 'Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats'. Together they form a unique fingerprint.

Cite this